ESTRO 2024 - Abstract Book

S6021

RTT - Treatment planning, OAR and target definitions

ESTRO 2024

Conclusion:

MRIgART significantly improved target coverage and reduced urethra dose. Organ motion and deformation between MRI session and MRI verification marginally diluted the benefit of adapting. Employing a no-action level correction strategy on the MRI verification or baseline shift correction would likely reduce this effect. MRIgART did not reduce rectum volume receiving 3600cGy or bladder volume receiving V3700cGy across the group, however a benefit was seen for some patients. Further work is underway to characterise patient anatomy most likely to benefit from MRIgART.

Keywords: Prostate cancer, MRI-guided, adaptive radiotherapy

References:

1. Pathmanathan AU, van As NJ, Kerkmeijer LG, Christodouleas J, Lawton CA, Vesprini D, van der Heide UA, Frank SJ, Nill S, Oelfke U, Van Herk M. Magnetic resonance imaging-guided adaptive radiation therapy: a “game changer” for prostate treatment?. International Journal of Radiation Oncology* Biology* Physics. 2018 Feb 1;100(2):361-73. 2. Dunlop A, Mitchell A, Tree A, Barnes H, Bower L, Chick J, Goodwin E, Herbert T, Lawes R, McNair H, McQuaid D. Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac. Clinical and translational radiation oncology. 2020 Jul 1;23:35-42.

3. Tocco BR, Kishan AU, Ma TM, Kerkmeijer LG, Tree AC. MR-guided radiotherapy for prostate cancer. Frontiers in Oncology. 2020 Dec 9;10:616291.

4. PACE RADIOTHERAPY PLANNING AND DELIVERY GUIDELINES. https://www.icr.ac.uk/media/docs/default source/default-document accessed 20.10.23